<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739476</url>
  </required_header>
  <id_info>
    <org_study_id>QUEPRO</org_study_id>
    <secondary_id>GRS1855/A/18</secondary_id>
    <secondary_id>17/1358</secondary_id>
    <secondary_id>2016-004117-27</secondary_id>
    <nct_id>NCT03739476</nct_id>
  </id_info>
  <brief_title>Clinical Trial With Quetiapine Prophylaxis Postoperative Delirium in High Risk Surgical Patients</brief_title>
  <official_title>Controlled, Double-blind, Randomized Clinical Trial for Prophilaxis of Postoperative Delirium in High Risk Surgical Patients With Quetiapine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Biomédica de Salamanca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo Español de Rehabilitación Multimodal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blinded Clinical trial to test efficacy of Quetiapine versus placebo in reducing
      postoperative delirium in high risk surgical patients after three days of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates postoperative delirium in high risk surgical patients to know the
      incidence of postoperative delirium in patients at risk, over 65 years, treated early with
      prophylactic quetiapine versus placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>one arm treatment. one arm placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To Know the incidence of postoperative delirium in patients at risk, over 65 years, treated early with prophylactic quetiapine versus placebo.</measure>
    <time_frame>28 (± 2) days from the start of treatment in each patient.</time_frame>
    <description>Proportion of patients diagnosed with delirium (number of cases of delirium / total number of patients) within the first four days in both arms.
65 years, treated early with prophylactic quetiapine versus placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days without delirium, if it appears.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Number of days from the start of treatment until delirium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of delirium, if it appears.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapine.</time_frame>
    <description>Number of days with delirium, if it appears. Perceived quality of life.
Mortality (all causes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of delirium measured with a validated scale. time of appearance the duration and severity. use of another antipsychotics.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Severity of delirium measured with a the Delirium Rating Scale-Revised-98 (DRS-R-98).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of other antipsychotic (haloperidol).</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Total dose (mg) of other antipsychotic to control symptoms of delirium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of sedation.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Degree of sedation measured with a validated scale Richmond Agitation-Sedation Scale (RASS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of QTc prolongation.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Increased (msec) ECG control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of extrapyramidal symptoms.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Presence o absence of extrapyramidal symptoms (tremor, involuntary movements, rigidity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in hospital from surgery.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Number of days from surgery until discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived general well-being.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Evaluation of quality of life using Short Form-36 Health Survey questionnaire (SF36).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (all causes)</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Mortality at discharge and at 28 (± 2) days before the start of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Postoperative Delirium</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine 25 miligrames 1 hour after surgery and each 12 hours for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 hour after surgery and each 12 hours for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine 25 milligrams capsule</intervention_name>
    <description>Compare the incidence of postoperative delirium.</description>
    <arm_group_label>Interventional</arm_group_label>
    <other_name>Experimental arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Compare the incidence of postoperative delirium.</description>
    <arm_group_label>control</arm_group_label>
    <other_name>Control arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than or equal to 65 years-old patients who will be undergoing major surgery
             (noncardiac) and having an equal or greater score of 5 on the scale Delphi.

          -  Age: 70-79 years: 1 point; ≥80 years: 2 points.

          -  Physical activity: need for assistance, not self-sufficient: 2 point.

          -  Alcoholism: 1 point.

          -  Hearing Impaired: 1 point.

          -  History of delirium: 2 points.

          -  Emergency surgery: 1 point.

          -  No laparoscopic surgery: 2 points.

          -  Admission critical Units: 3 points.

          -  Value of C-reactive protein (CRP)≥ 10 mg (milligrms) / dL (decilitre): 1 point

        Exclusion Criteria:

          -  Allergy to quetiapine.

          -  Patients with a score less than 5 on the Delphi scale.

          -  Diagnosis of delirium at admission.

          -  Cardiological diseases: qtc ≥ 460 mseg (millisecond) in men, ≥ 470 msec (millisecond)
             in women, recent MI or cardiac decompensation, 2-3 ° AV block or history of torsades
             de pointes arrhythmias or ventricular arrhythmias, bradycardia...

          -  Hypokalemia ≤ 3 mEq / CLK.

          -  History of drug use.

          -  Patients on Antipsychotic or antidopaminergic treatment (chlorpromazine, clozapine,
             olanzapine, risperidone, haloperidol, quetiapine, paliperidone, amisulpride).

          -  Parkinson's disease.

          -  Test MINIMENTAL ≤ 24.

          -  Corps or vascular dementia Levi.

          -  Hypokinetic movement disorder.

          -  History of neuroleptic malignant syndrome.

          -  Central Anticholinergic Syndrome.

          -  Epilepsy.

          -  Patients with a wight less than 50 or greater than 200 kg (kilograms).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisa Sanchez-Barrado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa Sanchez-Barrado, MD</last_name>
    <phone>+34 923 291100</phone>
    <phone_ext>55177</phone_ext>
    <email>mesanchezba@saludcastillayleon.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carmen Arias, PhD</last_name>
    <phone>+34 923210960</phone>
    <email>ensayosclinicos@ibsal.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Sanchez Barrado, Md</last_name>
      <phone>+34 923 291100</phone>
      <phone_ext>55177</phone_ext>
      <email>mesanchezba@saludcastillayleon.es</email>
    </contact>
    <contact_backup>
      <last_name>Carmen Arias, pHD</last_name>
      <phone>+34923210960</phone>
      <email>ensayosclinicos@ibsal.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative</keyword>
  <keyword>Delirium</keyword>
  <keyword>Quetiapine</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

